Trial · NCT03060629
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment | Group 1: Ad26.Mos.HIV Vaccine | 54 | Participants | ||
| Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment | Group 2: Placebo | 65 | Participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After First Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 34.2 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After First Vaccination | Group 2: Placebo | 9.4 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After Second Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 20.0 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After Second Vaccination | Group 2: Placebo | 8.1 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After Third Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 25.2 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After Third Vaccination | Group 2: Placebo | 8.9 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After Fourth Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 25.7 | Percentage of participants | ||
| Percentage of Participants With Local Reactogenicity Signs and Symptoms After Fourth Vaccination | Group 2: Placebo | 8.6 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After First Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 52.9 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After First Vaccination | Group 2: Placebo | 40.9 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Second Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 33.2 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Second Vaccination | Group 2: Placebo | 28.6 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Third Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 31.5 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Third Vaccination | Group 2: Placebo | 26.8 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Fourth Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 29.4 | Percentage of participants | ||
| Percentage of Participants With Systematic Reactogenicity Signs and Symptoms After Fourth Vaccination | Group 2: Placebo | 23.6 | Percentage of participants | ||
| Percentage of Participants With Unsolicited Adverse Events (AEs) for 30 Days After First Vaccination | Group 1: Ad26.Mos.HIV Vaccine | 16.6 | Percentage of participants | ||
| Percentage of Participants With Unsolicited Adverse Events (AEs) for 30 Days After First Vaccination | Group 2: Placebo | 14.8 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03060629/results